Biosynthesis and functions of human milk oligosaccharides (HMO) are not well known. A typical housekeeping enzyme, b1,4-galactosyltransferase, links galactose to glucose to form lactose which is then used as backbone for the assembly of HMO. We investigated whether milk lactose and HMO may be labeled in vivo by an orally given 13 C-galactose bolus. Eleven exclusively breastfeeding mothers were given a 13 Cgalactose bolus at the end of their breakfast. Milk and urine samples from each nursing up to 36 h were analyzed for carbohydrate composition by high-performance thin-layer chromatography, high-pH anion-exchange chromatography, and fast atom bombardment mass spectrometry. 13 C enrichment of milk fractions, urinary carbohydrates, lactose, and oligosaccharides as well as of breath CO 2 was determined by isotope ratio mass spectrometry. Up to 10% of the orally given galactose bolus was directly transported to the mammary gland and incorporated into milk components. Characteristic for most milk samples was the appearance of two 13 C-peaks, the first immediately after the 13 C-bolus was taken and the second on the next morning. The highest 13 C enrichment was found in lactose followed by neutral and acidic oligosaccharides. In breath samples, the 13 C-excretion followed the same pattern as in milk.
Introduction
The human mammary gland is a unique tissue, because it is thought to be the only organ where lactose and lactosederived oligosaccharides can be synthesized (Brew and Hill, 1975; Kobata et al., 1978; Charron et al., 1998) . A β1,4-galactosyltransferase as housekeeping enzyme links galactose to glucose instead of GlcNAc to form lactose which is then used for the assembly of human milk oligosaccharides (HMO) present in concentrations of about 5-10 g/L (Kunz et al., 2000) . The quantity and the pattern of HMO are affected by the expression of specific glycosyltransferases in the mammary gland. Genes encoding for the Lewis type blood group and the secretor status determine the presence of α1-2-, α1-3-and/or α1-4-fucosylated core structures of HMO (Watkins and Morgan, 1957; Egge, 1992) . In addition, different patterns of sialylation, that is, α2-3-and/or α2-6-linkages of N-acetylneuraminic acid (NeuAc), increase the variability of HMO to a number of >150 compounds characterized so far (Egge et al., 1983; Stahl et al., 1994; Kunz et al., 2000) .
HMO are discussed to play an important role in the infants' defense against certain infections and during inflammatory processes (Zopf and Roth, 1996; Sharon and Ofek, 2000) . For example, they may promote the growth of a non-pathogenic intestinal microflora or function as receptor analogs preventing the epithelial attachment of pathogenic micro-organisms. Recently, it has been shown that they inhibit leukocyte adhesion to activated endothelial cells, and they may influence neutrophil platelet interactions (Bode, Kunz et al., 2004; Bode, Rudloff et al., 2004) .
Despite an increasing number of animal and preclinical studies (Idäänpään-Heikkil et al., 1997; Mysore et al., 1999) , the in vivo evidence for specific functions of HMO in the infant is still lacking. To perform functional studies in humans, it would be of great advantage to achieve an in vivo labeling of milk oligosaccharides to be able to follow their metabolic fate in the recipient infant.
Thus, we used a straightforward approach and orally applied 13 C galactose to lactating mothers investigating whether or not this monosaccharide is directly used for the biosynthesis of the large amounts of lactose (50-70 g/L) as well as of oligosaccharides (5-10 g/L), without being metabolized by the liver first. Because (a) milk biosynthesis can be turned on to a maximum within a few minutes, (b) the amount of milk produced by a women can reach up to several liters a day, and (c) galactose but not glucose is a main component in HMO, we assumed that it could be an advantage to offer galactose instead of glucose to the lactating mammary cell. Previously we explained our hypothesis that orally given galactose is incorporated into milk lactose and oligosaccharides (Kunz et al., 2000) . We exemplified the potential of applying stable isotopes to lactating mothers and monitoring the metabolic fate in their infants by reporting the data from one mother-infant pair. Also, we demonstrated earlier analyzing milk from one woman that the application of 2 g 13 C-galactose not only leads to a 13 C-enrichment of whole milk but of lactose as well as of neutral and acidic oligosaccharide fractions (Obermeier et al., 1999) . As an extension of our previous work, we describe here for the first time the applied methods, we increased the amount of the 13 C-bolus to 4 g 13 C-galactose, and we demonstrate the efficacy of the method in 11 other mothers. These women received a 13 C-galactose bolus with either 2 or 4 g 13 C galactose immediately after breakfast. In addition, we wanted to quantitate the amount of galactose which is directly incorporated into lactose and lactose-derived oligosaccharides. Moreover, if the 13 C enrichment of oligosaccharides was high enough, investigations on the metabolic fate of a particular component in the recipient infants and on the amount an infant receives per day should be possible in subsequent studies.
Results

C enrichment of whole milk and CO 2 -breath tests
After the oral 13 C-galactose bolus had been given, there was an immediate, marked 13 C enrichment of the whole milk in the first 4-8 h (Figure 1 ). Then, a fast decline of the δ 13 C PDB values followed. Individual differences were observed in the intensities of the first 13 C peaks and the presence of a second 13 C peak in the morning of the next day. In milk from four women, the 13 C enrichment on the second day was as high or even more pronounced than that on the first day (Figure 1 ).
13 C enrichment of breath was determined for nine of 11 mothers by analyzing 13 CO 2 . The 13 CO 2 exhalation over 36 h resulted in a similar curve compared to the 13 C enrichment of whole milk (Figure 2 ).
Cumulative
13 C enrichment of whole milk, breath, and urine
The 13 C cum enrichment in milk on day 1 was between 3.3 and 10.5% of the oral 13 C dose (Table I ). Table I also shows the 13 C cum enrichment in breath and urine of the mothers on the first day in a range between 14.8 and 40.9% and 0.7 and 1.4%, respectively.
C enrichment of milk fractions
Due to the high δ 13 C PDB in whole milk, we addressed the question whether or not a specific 13 C enrichment occurs in one particular milk fraction. As a representative example, Figure 3 shows that δ 13 C PDB in the carbohydrate fraction from the first milk samples of one mother was more than twice as high as in whole milk. The course of the 13 C enrichment of the carbohydrate fraction was in parallel to that of whole milk. The 13 C enrichment of the protein fraction, however, was less than half that of whole milk. In the fat fraction, the δ-values were found to be almost baseline level.
Composition and
13
C enrichment of the carbohydrate fraction To characterize milk carbohydrates and to determine their 13 C enrichment, we defatted, deproteinized, and separated whole milk by Sephadex G25 gel filtration into five fractions with components of various molecular weights (Figure 4) . Investigations of the composition of these fractions by high-performance thin-layer chromatography (HPTLC) (Figure 4 , inset), high-pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) ( Figure 5 ), and fast atom bombardment mass spectrometry (FAB-MS) revealed the following composition of the Sephadex G25 fractions: mainly acidic oligosaccharides in fractions 1 and 2, mainly complex neutral components in fraction 3, neutral oligosaccharides in fraction 4, and mainly lactose in fraction 5.
δ 13 C PDB of each Sephadex G25 fraction of all milk samples during 36 h from all participants revealed in most samples the highest δ 13 C enrichment in lactose followed by fractions with mainly neutral oligosaccharides and acidic components ( Figure 6 ). However, in some samples the 13 C enrichment of neutral and acidic components was similar to or even higher than that of lactose ( Figure 6 ).
Isotope ratio mass spectrometry of 13 C-lactose and 13 C-oligosaccharides
Due to the high 13 C content not only in lactose but also in neutral and acidic oligosaccharides, we collected single peaks after HPAEC-PAD and determined their structure by FAB-MS as well as their δ 13 C PDB by isotope ratio mass spectrometry (IRMS). Especially those fractions which contain lacto-N-tetraose and fucosyl-lacto-N-tetraose were highly 13 C-enriched compared with the baseline values (-26‰). Even more complex components such as difucosyl-lacto-Ntetraose, fucosyl-lacto-N-hexaose or difucosyl-lacto-N-hexaose were highly 13 C-enriched. 
13
C enrichment of whole milk and of milk fractions from one woman after an oral galactose bolus (2 g 13 C-galactose and 25 g galactose) was given (see also legend to Figure 1 ). Milk aliquots were collected from each suckling over a period of 36 h. Whole milk ■, fraction with carbohydrates ▲, proteins ❏, and fat ❍. . Sephadex G25 gel filtration of a defatted and deproteinized milk sample and thin layer chromatography (inset) of the resulting carbohydrate fractions. Carbohydrates were visualized by spraying the HPTLC plates with an orcinol reagent according to Kunz et al., 1996. Incorporation of 13 C into lactose and quantitation of the contribution of orally ingested galactose to lactose biosynthesis To investigate how much of the oral 13 C-galactose is directly incorporated into milk lactose, we performed 13 C-NMR studies. To find out on which position within the lactose molecules the 13 C-label was located, we isolated 10-20 mg lactose from each milk sample of all 11 women throughout 36 h. In all samples, the 13 C atom was present only in the C 1 -position of galactose and C 1 -position of glucose within the lactose molecule. An example is given in Figure 7 and Table II. The amount of oral galactose which was directly incorporated into lactose was calculated for the first milk sample, after the 13 C-galactose bolus was given. The individual variation in the 11 mothers was between 0.4 and 19.4%.
Urine analysis
The cumulative 13 C-elimination rate in urine was calculated to be 0.8-1.0% of the ingested dose. Because the excretion of enzymatically determined galactose content in urine was in parallel to the corresponding 13 C PDB values, 13 C most likely originates from the ingested free 13 C-galactose. C-NMR analysis of a lactose sample isolated from the first milk sample collected after the 13 C-galactose bolus (in black) was given and of a lactose standard (in grey). As reference the C-4-signal of glucose was set to 1.00. Because glucose is localized at the reducing end of the lactose molecule, in the 13 C-NMR experiment it appeared twice, as α-and as β-Glc (see corresponding Table II) .
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http://glycob.oxfordjournals.org/ Downloaded from 1999 and unpublished data). In the course of the study, we increased the ratio of 13 C-galactose/galactose (4 g 13 C-galactose + 23 g galactose) with the intention to increase the 13 C enrichment of milk which would be an advantage in succeeding metabolic studies.
The application of 25 g non-labeled galactose is based on earlier observations by Lundblad and coworker that the intake of 25 g galactose or 50 g of lactose but not of 25 g glucose by healthy men leads to the urinary excretion of blood group active pentasaccharides some of which contain lactose as backbone (Lundblad et al., 1973) . This phenomenon can still not be explained, because the lactating mammary gland is considered to be the only organ capable of lactose synthesis; however, since that time, it has also been intriguing to speculate that orally given monosaccharides other than glucose may directly affect glycoconjugate biosynthesis. Recent studies support these observations. In patients with congenital disorders of glycosylation (CDG) syndrome Ib, an oral mannose treatment leads to a significant improvement of the clinical conditions (Niehues et al., 1998) . A further example is the oral application of fucose to a patient with CDG-IIc revealing improved fucosylation of glycoproteins and reduced recurrent infections (Etzioni et al., 2000) . Applying 13 C-galactose to lactating mothers, we found that in milk of nine of 11 women, two 13 C-peaks were observed; the first one shortly after the galactose bolus was taken in and the second one in the morning of the next day. We suggest that the rise in 13 C on day 2 is due to the mobilization of 13 C-glucose from liver glycogen. This assumption is also based on studies regarding liver glycogen metabolism (Shulman et al., 1990) .
Comparing the 13 C enrichment of whole milk and 13 CO 2 in breath, most of the ingested galactose is obviously used in metabolic processes as can be concluded from the increased exhalation of 13 CO 2 (Figure 2 ). Up to 40% of the oral 13 C dose can be detected in breath (Table I) . The large individual variation may be due to a different turnover, nutritional status, or metabolic activity of the liver. The cumulative 13 C enrichment in milk varies between 3.3 and 10.5% calculated for the first 15-20 h. After separating milk into different fractions, we found the highest enrichment in carbohydrates. With regard to the 13 C enrichment of carbohydrate fractions, we observed that not only lactose but also neutral and acidic oligosaccharides are highly 13 Cenriched. In some samples the enrichment was similar or even higher than that of lactose (Table II) . Considering the complex structures of oligosaccharides, there might be specific mechanisms ensuring a preferential incorporation of 13 C-galactose into oligosaccharides. This mechanism obviously guarantees the conversion of glucose into galactose even 36 h after the 13 C-bolus was given.
Due to the large amount of lactose in milk, we were able to isolate 10-20 mg from each sample to perform 13 C-NMR measurements. The analysis of more than 200 samples convincingly demonstrated without any exception that only the C1-atom of galactose and C1-atom of glucose within the lactose moiety represented 13 C. Because the 13 Cgalactose ingested by the women was 99% labeled with 13 C at the C1-position, the 13 C-labeled galactose must have been used directly or after epimerization of the 13 C-galactose to 13 C-glucose for the biosynthesis of milk carbohydrates. A complete epimerization of the 13 C-galactose into 13 C-glucose before the incorporation seems unlikely for the following reasons: in seven of the 11 women we observed a greater enrichment of C1-galactose in comparison with C1-glucose by 13 C-NMR in the first milk sample. In addition, in an experiment prior to the current study, 13 C-NMR of lactose from milk of a subject with only 1 g 13 C-galactose revealed a weak 13 C enrichment within the galactose moiety only, whereas glucose remained unlabeled. Also, preliminary 13 C-NMR of isolated lacto-N-tetraose revealed only a 13 C-atom on position 1 of both galactose moieties but not on glucose or GlcNAc (data not shown).
Taken together, these results expand our current information about oligosaccharide biosynthesis. Besides glucose which obviously plays a unique cellular role in the synthesis of N-linked glycans, (Spiro, 2000) galactose seems to be important as well in special situations such as lactation. Certainly, glucose itself is also used for the biosynthesis of carbohydrates as has been found in recent studies investigating lactose biosynthesis (Sunehag et al., 2002) . However, the question which arises from our study is whether or not it is of greater advantage from an energetic and physiological point of view to reserve glucose as a substrate for the maintenance of glucose homeostasis and intermediate metabolism. Our data are in line with the conclusion of Sunehag et al. (2002) studying lactose production that although adequate carbohydrate supply is important for lactogenesis, processes independent of glucose availability are required to maintain lactose production. In conclusion, this study provides evidence for the preferred incorporation of orally given galactose into milk lactose and oligosaccharides in lactating women. A surprisingly high 13 C-enrichment not only of lactose but also of neutral as well as of acidic oligosaccharides can be achieved by an in vivo labeling through the oral ingestion of 13 C-galactose. Thus, a physiological approach for labeling milk components facilitates further studies on their metabolic fate in the recipient infants.
Materials and methods
Subjects and study design
Exclusively breast feeding women (n = 11; 1-5 months postpartum) participated in the study. Some dietary restrictions, that is, the avoidance of naturally 13 C-rich food (e.g. corn, pineapple, fish) were given. Age and body weight of the mothers and their term infants as well as the number of infants were recorded. The mothers were asked not to drink milk for breakfast on the study day and to keep a brief record of their food intake during the study period. All women volunteered to participate in the studies which were approved by the ethical committees of the University in Dortmund and the University of Giessen.
Between 8:00 and 9:30 AM immediately after breakfast, the women orally ingested a galactose bolus consisting of 25 g galactose + 2 g 13 C-galactose (n = 7) or 23 g galactose + 4 g 13 C-galactose (n = 4). The purity of 13 C-galactose (D-galactose; 1 -13 C, 99%) from Promochem (Wesel, Germany) or from Eurisotop (Saint-Aubin Cedex, France) was determined by NMR to be more than 99%. The galactose bolus was ingested after dissolving in a total of 40-50 mL tap water.
Milk, urine, and breath sampling of the women
A milk sample (5-10 mL) was collected immediately before the galactose bolus was given (baseline value) and at the beginning of each nursing during the following 36 h. At the same time, a breath sample was also taken by the mother, and her urine was collected in 3-4 h intervals.
Separation of milk fractions and characterization of milk carbohydrates
The separation of whole milk into fractions with fat, proteins, and carbohydrates followed by the isolation of lactose from oligosaccharides has been achieved by ultracentrifugation, acetone treatment and gel filtration chromatography as described earlier (Kunz and Lönnerdal, 1989; Kunz et al., 1996) . Then, neutral and acidic HMO were characterized by chromatographic and mass spectrometry as follows.
High-performance thin-layer chromatography
An aliquot of each Sephadex G25 fraction (4 μL) was subjected to silica-HPTLC plates together with mono-and oligosaccharide standards. They were developed twice in butanol/acetic acid/H 2 O (2.5/1/1; v/v/v) or butanol/ethanol/ H 2 O/acetic acid/pyridine (5/50/15/1. 5/5; v/v/v/v/v) and then sprayed with orcinol for carbohydrate detection (0.1% orcinol in 20% H 2 SO 4 ) or ninhydrin reagent (0.3 g ninhydrin in 95 mL 2-propanol containing 5 mL 96% acetic acid) (Kunz et al., 1996) .
High-pH anion-exchange chromatography with pulsed amperometric detection
The system used for HPAEC-PAD of neutral and sialylated oligosaccharides consisted of a Dionex Bio-LC gradient pump, Carbo Pac PA-1 column (250 × 4.6 mm ID) equipped with a guard column and a Model PAD 2 detector (Dionex, Sunnyvale, CA) (Kunz et al., 1996) . Neutral and acidic oligosaccharides were analyzed by HPAEC-PAD using the following conditions: Eluent A, 100 mM NaOH; Eluent B, 100 mM NaOH and 250 mM Na-acetate. The elution program began with 3 mL of buffer A, followed by a gradient of up to 100 % buffer B in 30 min. A re-equilibration volume of 5 mL buffer A was chosen. The flowrate of 1.0 mL/min was used, and 25 μL of 1 or 4 mg/mL solutions were injected. Molar response factors was determined by injecting 3-6 times equimolar amounts of each oligosaccharide as described previously.
Fast atom bombardment mass spectrometry
Oligosaccharides (50-100 μg) were dissolved in 500 μL of pyridine/acetic anhydride (1/1; v/v). The mixture was stirred at room temperature overnight. Then the solvent was evaporated under nitrogen, and the residue was used for mass spectrometric analysis without further purification. The FAB-MS analysis was carried out on a VG-ZAB-T four sector instrument (Fisons Instruments, Manchester, UK); cesium was used for atom bombardment. The applied acceleration voltage was 8 kV. Thioglycerol/m-nitrobenzylalcohol (1/1; v/v) was used as matrix to which 1 μL of a homogeneous sample solution in chloroform/methanol (1/1; v/v) was added. For spectra recording, positive ions (FAB + ) were detected after the first electrostatic analyzer on the second photomultiplier point detector. The spectra were run in a mass range from 100 to 2500 atom mass units with a scan rate of 8 s per decay and up to 10 scans were accumulated. For data acquisition and processing, the software Opus V3 was used (Pohlentz et al., 1994) .
Determination of total organic carbon
Determination of total organic carbon (TOC) was carried out using a Total Carbon Analyzer (TOC-5000/5050; Shimadzu Europa GmbH, Duisburg, Germany). Briefly, 10 mL diluted milk (1:500) or urine (1:200) was combusted at 680°C. CO 2 produced originating from total carbon (TC) was dried and then, after removal of the halogens by an absorbing material, measured with a non-disperse infrared gas analyzer (NDIR) at a wavelength of 4.3 μm. To determine the amount of inorganic carbon (IC), we added an acidic IC reagent (H 3 PO 4 ) to the sample, and the CO2 released was detected by the NDIR. TOC (mg/L) was calculated by subtracting IC from TC. The absolute amount of TOC (g) in each sample was determined according to the equation
-3 , with V sa as sample volume.
For milk, the V sa was the volume of each feeding derived by weighing the infant before and after nursing and dividing this weight by the specific density of milk (ρ = 1.031 g/mL). For urine, V sa was the excreted volume over the collection period.
Determination of
13
C enrichment by isotope ratio mass spectrometry 13 C enrichment was determined as δ 13 C PDB measured in duplicate in whole milk, milk carbohydrates, urine, and urinary carbohydrates by IRMS (Delta S, Finnigan MAT, Bremen, Germany) after total combustion at 1020°C (NA 1500 Series 2, Carlo Erba Instruments, Rodano, Italy). Breath samples were analyzed in a BreathMat IRMS (Finnigan MAT). 13 C elimination rates were then quantified as described below.
Mass spectrometric 13 C analysis by IRMS The 13 C content of a sample is expressed as delta value (δ 13 C PDB ) (‰) which is the relative difference between the 13 C/ 12 C ratio of a sample (sa) and the international Pee Dee Belemnite (PDB) standard with a ( 13 C/ 12 C) PDB ratio of 0.0112372 (Schoeller et al., 1980 O content of the sample and the blank correction for the carbon of the tin cups (Craig, 1957) . For an easier comparison of the data, the results were expressed as Δδ 13 C PDB (corrected for the 13 C/ 12 C ratio at baseline). The accepted standard deviation was <0.2‰ for total urine and isolated carbohydrates and <0.7‰ for total milk. The accepted deviation for breath sample analyses was <0.3‰.
Calculation of the cumulative 13 C enrichment in milk and urine
To determine the 13 C enrichment in milk and urine, TOC and the 13 C content (atom%) for each sample were measured. Then, the excreted amounts of 13 C were calculated, taking into account the baseline 13 C values and the 13 C bolus given. Using this 13 C-at% sa and the TOC of a sample, we then calculated the absolute amount of 13 C of each sample (sa) as follows:
Calculation of the cumulative 13 
C exhalation
The percentage recovery of the ingested 13 C amount in breath ( 13 C cum ) was calculated using the equation shown above. Thereby, the exhaled 13 C amount is defined as 13 C excreted (mol/kg) = Δδ 13 C cum (‰ · h) 13 R PDB × CO 2 -P (mmol/kg · h) with Δδ 13 C cum being the cumulative 13 C exhalation calculated according to the trapezoidal rule described by Schoeller et al. (1980) , and CO 2 -P as the individual CO 2 production of the subject. CO 2 -P was estimated taking into account the basal metabolic rate, age, weight, height, and activity levels of the subject according to Schofield (1985) .
13
C nuclear magnetic resonance analysis Twenty milligrams of lactose isolated from human milk or a lactose standard was dissolved in deuterated water (D 2 O). After the addition of 5 μL 2 M NH 4 OH, the samples were analyzed in a proton decoupled 13 C experiment at 25°C with 1024 scans in a magnetic field of a strength of 11.74 Tesla (AMX 500 NMR-Spektrometer, Bruker, Karlsruhe, Germany). The processing of the 13 C experimental results was performed using the software XWinNMR (Bruker). To determine 13 C enrichment and to take into account the different relaxation times of single 13 C atoms, the analysis was referred to a lactose standard. Here, the C-4 signals were arbitrarily set to 1.00. This means that the intensity of the C-4 signal corresponded to the natural 13 C abundance of 1.1%.
Determination of galactose and lactose content
Galactose and lactose contents of milk and urine were photometrically determined using a colorimetric kit from Boehringer Mannheim (Mannheim, Germany). 
